MANF, human recombinant
P-101-100
Datasheet as| Name | MANF, human recombinant |
| Synonyms | Mesencephalic astrocyte-derived neurotrophic factor – MANF; ARMET; ARP |
| Uniprot ID | P55145 |
| Source | Human |
| MW | Approximately 18.1 kDa, a single non-glycosylated polypeptide chain containing 158 amino acids |
| Host | CHO-based cell line (expressed by QMCF Technology) |
| Purification | Purified by ion-exchange chromatography and gel-filtration from serum-free CHO growth media |
| Concentration | 1 mg/ml Concentration of the protein is determined by BCA Protein Analysis kit (Pierce). BSA was used as a standard |
| Buffer | PBS pH 7.4, concentration |
| Endotoxine | Less than 1EU/mg of protein as determined by LAL method |
| Bioproperties | Protein is biologically active. Suitable for cell culture and in vivo testing. Human recombinant MANF has been tested in rat 6-OHDA model of Parkinson's disease and shown neureprotection and neurorestoration. MANF has also shown neuroprotection in animal models of stroke |
| QC | SDS-PAGE and Western-Blot analysis (Figure 1 and 2); Mass-spectroscopy: Purified human MANF is characterized as homogenous material by mass-spectroscopy |
| Background | MANF is a trophic factor for midbrain dopamine neurons in vivo. It prevents the 6-OHDA- induced degeneration of dopamine neurons in rodent models of Parkinson’s disease (Lindholm et al., 2008, Voutilainen et al., 2009). When administered after 6-OHDA-lesioning it restores the dopaminergic function and prevents degeneration of dopamine neurons in substantia nigra pars compacta |
| Shipping | Shipped in dry-ice |
| Storage | Store at -70°C upon receipt. Recommended to aliquot into smaller quantities. Avoid repeated freeze-thaw cycles |
| Related Products | Polyclonal and monoclonal antibodies against human MANF For more information please visit: www.icosagen.com/antibodies |
| References | Lindahl, M et al. 2014. MANF is Indispensable for the Proliferation and Survival of Pancreatic β Cells. Cell Reports 7, 366-375 Bäck, S et al. 2013. Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease.Brain and Behavior 3(2): 75-88 |
Figure 1. SDS-PAGE analysis of human MANF visualized by PageBlue protein staining solution (Fermentas). Line 1. Protein size marker (PageRuler Prestained protein ladder, Fermentas); Line 2. 10 µg of MANF.
Figure 2. Western Blot testing of human MANF using anti-MANF polyclonal antibody (Icosagen AS Cat. No 310-100). Line 1. PageRuler Prestained Protein Ladder (#SM0671 Fermentas); Line 2. Recombinant MANF expressed into the supernatant of CHO cell culture medium